Member Info for VanVan

AGM tomorrow? Anyone going? Will we get a change of Chair?

XSpace on Monday ay 13.00 hrs. Podcast with Eddie etc.

Probably go to 100 Bitcoin after next purchase.

General Meeting on Friday to issue more shares.

Bitcoin remains strong and some expect an early uplift from here.

COIN doesn't seem as strong as Smarter Web Co. currently. That must change

Yellow announcement expected in July?

So lots to keep investors on their toes.

Another one announced on Monday at 13.00 hrs. Then General Meeting on Friday. Expect we will hit 100 bitcoin next week.

🚨 Join live this Monday 30 June for another #XSpaces with @ForzaBitcoin & @CoinsiliumGroup

@EddyBitcoin | @MalcolmPalle | @btcjvs

#Bitcoin #ForzaBitcoin $CINGF #COIN

Great news guys. Can we expect this to trigger buying & SP recovery. Will take a while for investors to wake up to this early afternoon RNS

I believe the Annual Report & Accounts are due end of this month.

These plus the signing off on the new Web site, launched yesterday, no doubt taking up a lot of director time.

SCANCELL HOLDINGS PLC will be holding a Clinical and Corporate Update meeting on 25th Jun 2025 at 11:00am BST.

Meeting Description:

Scancell to provide a general clinical and corporate update ahead of upcoming SCOPE and other clinical data.

Https://audioboom.com/posts/8738421-the-sunday-roast-bitcoin-treasury-priority-intelligence-ceo-james-sheehan-plus-zynx-s-500b

Podcast out

Https://audioboom.com/posts/8738421-the-sunday-roast-bitcoin-treasury-priority-intelligence-ceo-james-sheehan-plus-zynx-s-500b

Podcast out

Is this the SP reaction we had after previous raises? Presumably once this turns north again at some point in the near future. Has anyone been monitoring these patterns after raises 1 & 2 please?

Zak Mir seems to be suggesting the longer term chart indicates 50p but what then? Are there other examples of this sort of breakout which give us clue?

Strong RNS this morning

SWC is a 40 bagger since 1st May. COIN is up 4.7 times since 15th April. Long way to go yet perhaps? A 40 bagger would put us at around £1 a share.

HTtps://www.coindesk.com/policy/2025/06/06/uk-regulator-fca-to-lift-ban-on-crypto-etns-for-retail-investors

Great session. Worth a listen. They talked about the potential. Just need UK regulators to open doors to ETF’s & ETN’s. Bound to be positive knock on impact for the likes of Coinsillium. Apparently could be £5bn of inflows into these markets when FDA gives green light. They are expected to comment on the industry papers in 4 weeks, so not long to wait. Uk falling behind the world. Regulators aware. Also potentially £2 trillion in Pensions & ISA’s that could be targetted with these products.

Coinsillium financial results June.

New look website in course of construction.

Will also have a new Strategic Plan completed with links to new Web Site.

All their attention is on Forza. No doubt looking to ramp up opportunities to acquire more Bitcoin over short term.

No doubt lots of news-flow in relatively short term.

Anyone else with feedback/observations?

Scheduled for 1 0'clock I believe!

Got my new 6p shares this morning. Well done Coinsillium.

Ready to go again now. Can't see any reason it won't respond strongly again.

Musk has a view apparently that BTC could become the new world reserve currency. Wow. I would have preferred gold I must say.

Did anyone listen into the conference call this morning?

Amaroq were awarded the

"Prospector and Developer of the Year" award by the

Greenland

Government at @the_PDAC mining conference in

Toronto yesterday

Rest of message

Are the Data results in line with your expectations or better? Do the data results so far impress the wider market? Certainly not seen in the share price.

While we don’t typically comment on our share price, we are very excited by the positive data generated to date by SCIB1 in the ongoing SCOPE study. We reported 80% Progression Free Survival in 25 patients at 6 months, with 20% of patients achieving a complete response. In addition, a disease control rate of 84% was observed, as was an objective response rate (ORR) or 72%. These results far exceed what is currently achievable with double checkpoints alone, where ORR is around 48%, demonstrating the ability of SCIB1 to induce an immune response and fight cancer.

I received this email from the Co. this morning in response to my written questions that I submitted. Impressive to reply in such detail. Happy to share with LSE B.B.. Hope you find something of interest. Bit more to follow as won't all fit on one post.

Good morning, John,

Please find below responses to your questions submitted during Scancell’s Interim Results Presentation.

What has happened to Modi-1 treating TNBC & Ovarian cancer?

Data from patients receiving the Modi-1 cancer vaccine as a monotherapy showed that it was safe and well tolerated and demonstrated encouraging early efficacy in high grade serous ovarian carcinoma and triple negative breast cancer. The number of patients who have experienced long periods of stable disease following monotherapy with Modi-1 is encouraging. Based on this, it has been decided to evaluate Modi-1 in combination with checkpoint inhibitors, as first line therapy in advanced cancer.

Is there any interest beyond GlyMab?

Yes – we continue to see commercial traction around both our Glymabs® and AvidiMab® antibodies and are also having early conversations around the vaccines.

I think you earlier indicated in 2024 that you had active discussions 5 C0'c re: anti bodies. Is that still the case?

While we are unable to comment on specifics, active discussion with pharmaceutical and biotech companies are ongoing.

Are the Trials big enough to generate the level of interest we all hope for? They seem very small numbers. Are they considered statistically robust at these numbers?

The number of patients recruited into both the first stage of the Phase 2 SCOPE study and Phase 2a dose expansion ModiFY study fell within the parameters intended for these trials. Based on the positive results from the first stage of the SCOPE study, for instance, there was a greater than 90% probability that the second phase would also be successful, and we are incredibly excited about the exceptional data that has been reported from the first cohort investigating SCIB1. 43 patients have now been recruited into this cohort, which is due to report 25-week data in mid-2025, and further cohorts investigating next-generation vaccines iSCIB1+ and intradermal delivery continue strong recruitment, for a total of 43] patients.

We remain confident in the statistical robustness of our results.